BetterLife Pharma Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of nutraceuticals and pharmaceuticals. Its products include AP-001, AP-002 and AP-003. AP-001 is a topical formulation of recombinant human Intensified high-dose intravenous interferon alpha 2b (IFNa2b) based on its Biphasix drug formulation technology. The Biphasix formulation allows stable cream formulation of IFNa2b and its delivery across the dermis/mucosa, with minimal systemic exposure. AP-001 is developed to treat human papillomavirus (HPV) induced cervical intraepithelial neoplasia (CIN). AP-002 is an organo-gallium complex whose drug substance is tris (8-quinolinolato) gallium (III). AP-002 has direct anti-tumor activity as well as direct anti-osteoclast activity. AP-003 is an IFNa2b inhalation formulation. The Company is also engaged in developing psychedelic compounds, peptides, pro-drugs and nutraceuticals.